Ketim Therapeutics Welcomes Dr. Scott Fry, Ph.D., to Advisory Board
Ketim Therapeutics Announces New Advisory Board Member, Dr. Scott Fry, Ph.D.
Ketim Therapeutics is thrilled to welcome Dr. Scott Fry, Ph.D., to its Advisory Board. With extensive expertise in diagnostics and biotechnology, Dr. Fry’s career highlights include leading the successful launch of the first over-the-counter COVID-19 diagnostic test in the United States as Chief Operations Officer at Ellume Limited. His experience in scaling diagnostic solutions, including ELISAs for detecting various diseases, aligns perfectly with Ketim’s mission to transform perinatal mental health care.
“Dr. Fry’s strategic insights and vast experience will help us drive innovation and deliver impactful solutions for women’s health,” said Dr. Clarissa Yates, CEO of Ketim Therapeutics.
Ketim Therapeutics Appoints Dr Carrie Hillyard to Board of Directors
Ketim Therapeutics Welcomes Dr Carrie Hillyard AM to Board of Directors
Dr Carrie Hillyard AM, a trailblazer in life sciences and venture capital, joins Ketim Therapeutics' Board of Directors. With decades of experience in medical research, diagnostics, and start-up mentoring, Dr Hillyard's strategic insights will guide Ketim's mission to revolutionise maternal mental health through biomarker-driven solutions.
Ketim Therapeutics Announces the Appointment of Dr. Maciej Trzaskowski as Chief Scientific Officer
We are thrilled to announce the appointment of Dr. Maciej Trzaskowski, PhD as our new Chief Scientific Officer! His extensive background, including roles at King’s College London, QUT, and as Founder of Profenso, aligns perfectly with Ketim’s vision to transform mental health screening and therapeutic solutions. Stay tuned for what’s next as we push the boundaries of innovation together with an idea.
Ketim Therapeutics Unveils Promising Pilot Study Results in the Quest for Early Postpartum Depression Detection
Ketim Therapeutics has achieved a significant breakthrough in maternal mental health research with the successful completion of a pilot study examining blood samples from the Queensland Family Cohort Study. In collaboration with the Australian Genome Research Facility, Ketim identified an 11-protein biomarker signature linked to postpartum depression (PPD) risk, out of over 5,400 proteins screened. This finding could enable the early prediction of PPD, offering a lifeline to mothers at risk. The next phase involves validating these results in an independent birth cohort, a process already underway, bringing Ketim closer to developing a reliable, non-invasive screening tool that could transform maternal healthcare.
Ketim Therapeutics enters agreements with Mater Research
Ketim Therapeutics has partnered with Mater Research to advance predictive biomarker research for perinatal depression using Queensland Family Cohort data. Affecting 1 in 5 women, perinatal depression poses serious risks, yet early detection remains a challenge. By identifying blood-based biomarkers, Ketim’s AI-driven technology aims to equip clinicians with a powerful early detection tool for personalised care. This collaboration strengthens Ketim’s mission to bridge research and clinical application, setting a new standard for maternal mental health diagnostics.